cpass surrogate virus neutralization test (svnt)  (GenScript corporation)

Journal: Vaccines

Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients

doi: 10.3390/vaccines13020170

Figure Lengend Snippet: Antibody titers from the first and second blood samples by the participants’ demographics.

Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

Techniques: Infection, Sampling

Journal: Vaccines

Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients

doi: 10.3390/vaccines13020170

Figure Lengend Snippet: Locally estimated scatterplot smoothing curve based on data from the first blood sample collection, illustrating the relationship of antibody levels as follows: ( A – C ) inhibition rates (%) for the surrogate virus neutralization test (sVNT) against the wild-type (WT) strain, ( D – F ) inhibition rates (%) against the Omicron variant, and ( G – I ) IgG levels. The curves are plotted against the number of days since COVID-19 infection ( A , D , G ), the last vaccination ( B , E , H ), and the last exposure to COVID-19 ( C , F , I ). The blue line represents the regression line, and the shaded gray area indicates the 95% confidence interval.

Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

Techniques: Inhibition, Virus, Neutralization, Variant Assay, Infection

Journal: Vaccines

Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients

doi: 10.3390/vaccines13020170

Figure Lengend Snippet: Locally estimated scatterplot smoothing curve based on data from the second blood sample collection, illustrating the relationship of antibody levels as follows: ( A – C ) inhibition rates (%) for the surrogate virus neutralization test (sVNT) against the wild-type (WT) strain, ( D – F ) inhibition rates (%) against the Omicron variant, and ( G – I ) IgG levels. The curves are plotted against the number of days since COVID-19 infection ( A , D , G ), the last vaccination ( B , E , H ), and the last exposure to COVID-19 ( C , F , I ). The blue line represents the regression line, and the shaded gray area indicates the 95% confidence interval.

Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

Techniques: Inhibition, Virus, Neutralization, Variant Assay, Infection

Journal: PLOS Pathogens

Article Title: Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection

doi: 10.1371/journal.ppat.1012624

Figure Lengend Snippet: Peripheral blood samples obtained from the patient on the days indicated were tested by the quantitative Abbott Anti-RBD-CMIA (a) and the GenScript cPass sVNT (b) . Antibody levels detected by Anti-RBD-CMIA and sVNT are given as arbitrary units (AU)/mL, cut-off ≥50 AU/mL, and signal reduction (% inhibition, cut-off >30%) as compared to the negative control. The GenScript cPass sVNT was performed with technical duplicates at a serum dilution of 1:20. The cut-off of the sVNT is indicated by the horizontal dotted line. (c) Qualitative results of the Mikrogen line blot testing for Anti-N IgG, as well as Anti-S1 and Anti-RBD IgM and IgG, are indicated as follows: open squares: non-reactive, grey squares: reactive below cut-off, black squares: reactive above cut-off. Administration of bamlanivimab (B), first vaccination (V) and therapy with sotrovimab (S) is indicated by vertical dotted lines.

Article Snippet: The commercial surrogate virus neutralisation test cPass (GenScript Biotech) was used to quantify levels of antibodies inhibiting the binding of the RBD to ACE2 [ , ].

Techniques: Inhibition, Negative Control